Fairmount Funds Management LLC: COGENT BIOSCIENCES INC (COGT): Quarterly 13F Position History
As of Q1 2026, Fairmount Funds Management LLC reported 5,503,418 shares of COGENT BIOSCIENCES INC (COGT), worth $211.8M and representing 15.3% of its 13F equity book. Quarter-over-quarter share count change: 3,500,000 (-38.9%) . The position first appeared in Q4 2020 and has been disclosed across 22 13F-HR filings in Pactolio's tracked window.
- 5,503,418Shares Held (Latest Filing)
- $211.8MReported Market Value (Latest Filing)
- 15.3%Portfolio Weight (% of 13F Equity Book)
- 3,500,000Quarter-over-Quarter Share Change
- -$108.0MQuarter-over-Quarter Value Change
- 9,003,418Peak Reported Shares (Historical)
Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 22 quarter s
| Quarter | Shares | QoQ Share Change | Share Change (%) | Market Value | Weight | Implied Price |
|---|---|---|---|---|---|---|
| Q1 2026 | 5,503,418 | 3,500,000 | -38.9% | $211.8M | 15.3% | $38.5 |
| Q4 2025 | 9,003,418 | 0 | — | $319.8M | 24.3% | $35.5 |
| Q3 2025 | 9,003,418 | +2,777,777 | +44.6% | $129.3M | 11.6% | $14.4 |
| Q2 2025 | 6,225,641 | 0 | — | $44.7M | 5.8% | $7.2 |
| Q1 2025 | 6,225,641 | 0 | — | $37.3M | 5.8% | $6.0 |
| Q4 2024 | 6,225,641 | 0 | — | $48.6M | 4.8% | $7.8 |
| Q3 2024 | 6,225,641 | 0 | — | $67.2M | 5.5% | $10.8 |
| Q2 2024 | 6,225,641 | +1,500,000 | +31.7% | $52.5M | 5.9% | $8.4 |
| Q1 2024 | 4,725,641 | +1,166,666 | +32.8% | $31.8M | 3.5% | $6.7 |
| Q4 2023 | 3,558,975 | 0 | — | $20.9M | 2.2% | $5.9 |
| Q3 2023 | 3,558,975 | 0 | — | $34.7M | 4.2% | $9.8 |
| Q2 2023 | 3,558,975 | +800,000 | +29.0% | $42.1M | 5.9% | $11.8 |
| Q1 2023 | 2,758,975 | 0 | — | $29.8M | 5.1% | $10.8 |
| Q4 2022 | 2,758,975 | 0 | — | $31.9M | 5.1% | $11.6 |
| Q3 2022 | 2,758,975 | 0 | — | $41.2M | 7.6% | $14.9 |
| Q2 2022 | 2,758,975 | +1,200,000 | +77.0% | $24.9M | 5.7% | $9.0 |
| Q1 2022 | 1,558,975 | 0 | — | $11.7M | 2.8% | $7.5 |
| Q4 2021 | 1,558,975 | 0 | — | $13.4M | 4.4% | $8.6 |
| Q3 2021 | 1,558,975 | 0 | — | $13.1M | 4.8% | $8.4 |
| Q2 2021 | 1,558,975 | 0 | — | $12.6M | 5.2% | $8.1 |
| Q1 2021 | 1,558,975 | 0 | — | $13.7M | 5.8% | $8.8 |
| Q4 2020 | 1,558,975 | — | — | $17.5M | 6.3% | $11.2 |
Methodology & FAQ
How This Position History Is Sourced
Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares — a quarter-end mark, not the manager's cost basis. See the full methodology document for the normalization rules.
When did Fairmount Funds Management LLC first disclose a COGT position in 13F-HR filings?
Fairmount Funds Management LLC first reported COGENT BIOSCIENCES INC (COGT) on its 13F-HR filing for the period ending 2020-12-31 (Q4 2020). The position has appeared on 22 reported quarters within Pactolio's tracked window.
What was Fairmount Funds Management LLC's most recent quarter-over-quarter share-count change in COGT?
Between Q4 2025 and Q1 2026, Fairmount Funds Management LLC reduced its COGT position by 3,500,000 shares (-38.9%), leaving 5,503,418 shares at a market value of $211.8M.
Does the implied price-per-share represent Fairmount Funds Management LLC's cost basis in COGT?
No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.